Skip to main content
Premium Trial:

Request an Annual Quote

Zeptosens Licenses Reagents from Cell Signaling Technology

NEW YORK, April 19 (GenomeWeb News) - Zeptosens of Witterswil, Switzerland announced today that it has signed an agreement with Beverly, Mass.-based Cell Signaling Technology for the use of CST's reagents in Zeptosens' ZeptoMARK protein array platform.

 

The reagents used will include phosphospecific antibodies to kinases and other signaling molecules, according to the companies.

 

Financial details of the agreement were not disclosed.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.